分红方面，欧普康视A股上市后累计派现8.97亿元。近三年，累计派现5.26亿元。 机构持仓方面，截止2025年6月30日，欧普康视十大流通股东中，华宝中证医疗ETF（512170）位居第 五大流通股东，持股1780.26万股，相比上期增加30.07万股。易方达创业板ETF（159915）位居第六大 流通股东，持股1274.60万股，相比上期增加26.06万股。南方中证500ETF（510500）位居第七大流通股 东，持股795.40万股，相比上期增加113.13万股。香港中央结算有限公司位居第九大流通股东，持股 690.22万股，相比上期增加159.91万股。 资料显示，欧普康视科技股份有限公司位于安徽省合肥市高新区望江西路4899号，成立日期2000年10月 26日，上市日期2017年1月17日，公司主营业务涉及眼视光产品及相关配套产品的研发、生产、销售,以 及眼视光服务。主营业务收入构成为：硬性接触镜40.86%，框架镜等其他视光产品及技术服务 21.52%，医疗服务19.89%，护理产品12.57%，非视光类产品4.60%，其他(补充)0.55%。 欧普康视所属申万行业为：医药生物-医疗器械-医疗耗材。 ...

9月8日，欧普康视盘中上涨2.12%，截至09:39，报18.33元/股，成交3048.32万元，换手率0.25%，总市 值164.26亿元。 资金流向方面，主力资金净流出6.07万元，特大单买入131.76万元，占比4.32%，卖出153.00万元，占比 5.02%；大单买入369.29万元，占比12.11%，卖出354.12万元，占比11.62%。 欧普康视今年以来股价跌2.11%，近5个交易日跌1.13%，近20日跌2.86%，近60日涨22.61%。 资料显示，欧普康视科技股份有限公司位于安徽省合肥市高新区望江西路4899号，成立日期2000年10月 26日，上市日期2017年1月17日，公司主营业务涉及眼视光产品及相关配套产品的研发、生产、销售,以 及眼视光服务。主营业务收入构成为：硬性接触镜40.86%，框架镜等其他视光产品及技术服务 21.52%，医疗服务19.89%，护理产品12.57%，非视光类产品4.60%，其他(补充)0.55%。 欧普康视所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：智慧医疗、医疗器械、 跨境电商、中盘、融资融券等。 截至8月29日，欧普康视股东户数6 ...

Core Viewpoint - The stock of Opcon Vision has shown fluctuations with a slight increase of 2.05% on September 1, 2023, while facing a year-to-date decline of 1.63% and a recent drop over the last five trading days of 3.96% [1] Financial Performance - For the first half of 2025, Opcon Vision reported a revenue of 871 million yuan, representing a year-on-year decrease of 1.42%, and a net profit attributable to shareholders of 250 million yuan, down 22.93% year-on-year [2] - The company has distributed a total of 897 million yuan in dividends since its A-share listing, with 526 million yuan distributed over the past three years [3] Shareholder Information - As of August 20, 2025, the number of shareholders for Opcon Vision was 64,100, a decrease of 1.07% from the previous period, with an average of 10,432 circulating shares per person, an increase of 1.08% [2] - Major institutional shareholders include Huabao Zhongzheng Medical ETF, Yifangda Growth Enterprise Board ETF, and Southern Zhongzheng 500 ETF, with increases in their holdings compared to the previous period [3] Market Activity - On September 1, 2023, Opcon Vision's stock price was 18.42 yuan per share, with a trading volume of 165 million yuan and a turnover rate of 1.36%, leading to a total market capitalization of 16.507 billion yuan [1] - The stock has experienced a 60-day increase of 18.76%, contrasting with recent declines over shorter periods [1]

Core Viewpoint - The stock of Opcon Vision has experienced a decline in recent trading sessions, with a notable drop of 3.61% year-to-date and 5.40% over the last five trading days, indicating potential concerns among investors regarding the company's performance and market conditions [1][2]. Financial Performance - For the first half of 2025, Opcon Vision reported a revenue of 871 million yuan, reflecting a year-on-year decrease of 1.42%. The net profit attributable to shareholders was 250 million yuan, down 22.93% compared to the previous year [2]. - Since its A-share listing, the company has distributed a total of 897 million yuan in dividends, with 526 million yuan distributed over the last three years [3]. Shareholder and Market Activity - As of August 20, 2025, the number of shareholders for Opcon Vision was 64,100, a decrease of 1.07% from the previous period. The average number of circulating shares per shareholder increased by 1.08% to 10,432 shares [2]. - The stock's trading activity showed a net outflow of 28.29 million yuan from major funds, with significant selling pressure observed [1]. Business Overview - Opcon Vision, established on October 26, 2000, and listed on January 17, 2017, specializes in the research, production, and sales of optical products and related services. Its revenue composition includes hard contact lenses (40.86%), other optical products and technical services (21.52%), medical services (19.89%), nursing products (12.57%), non-optical products (4.60%), and other supplementary products (0.55%) [1]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device and consumables sector, and is associated with concepts such as ophthalmology, medical devices, smart healthcare, and health initiatives [1]. Institutional Holdings - As of June 30, 2025, notable institutional shareholders include Huabao Zhongzheng Medical ETF, Yifangda Growth Enterprise Board ETF, and Southern Zhongzheng 500 ETF, with increases in their respective holdings [3].